Semaglutide vs. Tirzepatide: Which Is Right for You?
The Two Leading GLP-1 Weight Loss Medications
Both semaglutide (Wegovy) and tirzepatide (Zepbound) are highly effective weight loss medications — but they work differently and may produce different results. Here is the evidence-based comparison to help you have an informed conversation with your provider.
How They Work
Semaglutide: GLP-1 receptor agonist only. Mimics the GLP-1 hormone to reduce appetite and slow digestion.
Tirzepatide: Dual GIP/GLP-1 receptor agonist. Targets both GLP-1 receptors AND GIP receptors for enhanced metabolic effects.
Weight Loss Results (Clinical Trial Data)
| Metric | Semaglutide | Tirzepatide |
|---|---|---|
| Average Weight Loss | ~15% | ~22% |
| Patients losing ≥20% | ~32% | ~57% |
| FDA Approval | 2021 (Wegovy) | 2023 (Zepbound) |
| Dosing | Weekly injection | Weekly injection |
Side Effects
Both medications have similar side effect profiles — primarily gastrointestinal (nausea, vomiting, diarrhea, constipation). These are typically most pronounced during dose escalation and improve over time. Tirzepatide may have slightly higher rates of GI side effects due to its dual mechanism.
How to Decide
The choice between semaglutide and tirzepatide should be made with your medical provider based on your health profile, insurance coverage, treatment goals, and how your body responds. Some patients try one and switch to the other if side effects are problematic or results are insufficient. A Tallahassee provider can help you weigh these factors.
Next Step: Schedule a weight loss consultation in Tallahassee to discuss which medication may be appropriate for you.